Healthcare Industry News: John Powers
News Release - September 6, 2011
New Reimbursement Codes for Intra-Operative Radiation Therapy (IORT)Reimbursement Codes effective January 1, 2012 will cover cancer patients for additional treatment options
SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)-- Friday September 2, 2011 the AMA released new Current Procedural Terminology (CPT) codes that will be reported by hospitals, physicians and ambulatory centers providing coverage for additional treatment options for cancer patients. The new CPT codes, 77425 Intraoperative radiation treatment (IORT) delivery, electrons, single treatment session and 77469 for Intraoperative radiation treatment management, open new options for a single radiation treatment session for cancer patients. Details specific to reimbursement will be announced later this year and the new codes will be available for use on January 1, 2012.
“We are pleased that the AMA and ASTRO supported these codes for electron IORT. By approving new CPT codes for electron IORT procedures, patients will have greater access to a single, two minute, radiation treatment during surgery. These patients will benefit from a reduction of up to seven weeks of external beam radiation, also reducing the toxicity of their treatment and providing a quick return their normal lives.” said John Powers, Chief Executive Officer of IntraOp. “We anticipate that these new codes will increase patient awareness and availability of electron IORT to cancer patients throughout the United States.”
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. The IntraOp Mobetron is a patented, self-shielded, mobile, linear accelerator that allows hospitals to provide electron IORT in existing operating rooms at the time of surgery. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Centers of excellence in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program. The Mobetron is used to effectively treat over 20 different cancer indications.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.